Send to a Friend Share

Needham & Co Upgrades Cepheid (CPHD) to Buy

October 14, 2009 8:58 AM EDT
CPHD Hot Sheet
Rating Summary:
    9 Buy, 3 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 1
Needham & Co upgrades Cepheid (Nasdaq: CPHD) from Hold to Buy. Price target $17.

To see more analyst ratings on CPHD Click Here.

Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for genetic testing in the clinical molecular diagnostic, industrial, and biothreat markets.

You May Also Be Interested In


Related Categories

Upgrades

Related Entities

Needham & Company

Add Your Comment





Follow StreetInsider.com On Twitter